Table 2.
EC90 (AZT, μg/mL)* | EC90 (ddI, μg/mL)* | EC90 (AZT+ddI, μg/mL)* | |||
---|---|---|---|---|---|
AZT | 3.9 ± 0.3 | ddI | 7.0 ± 0.4 | AZT + ddI | 3.6 ± 0.5 |
NG1/AZTTP | 1.5 ± 0.4 | NG1/ddITP | 1.6 ± 0.3 | NG1/AZTTP+ddITP | 0.9 ± 0.3 |
AP-NG1/AZTTP | 0.8 ± 0.5 | AP-NG1/ddITP | 1.7 ± 0.4 | AP-NG1/AZTTP+ddITP | 1.2 ± 0.2 |
NG2/AZTTP | 1.5 ± 0.3 | NG2/ddITP | 0.6 ± 0.2 | ||
NG3/AZTTP | 1.6 ± 0.3 | NG3/ddITP | 2.1 ± 0.5 | ||
NG4/AZTTP | 1 ± 0.2 | NG4/ddITP | 0.5 ± 0.1 |
EC90 values (means ± SEM) were calculated from the dose-effect curves obtained for each drug/nanoformulation in three-four independent experiments